Prognostic Impact of Monocyte to Lymphocyte Ratio in Clinical Outcome for Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Nouri‐Vaskeh, Masoud; Mirza-Aghazadeh-Attari, Mohammad; Pashazadeh, Fariba; Azami-Aghdash, Saber; Alizadeh, Hadi; Pouya, Parnia; Halimi, Monireh; Zarei, Mohammad

doi:10.31661/gmj.v9i0.1948

Cited by 14 publications

(10 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, NLR has been identified as a prognostic indicator of post-therapeutic recurrence and survival in patients with HCC [18], and some reports have focused on HAIC [15, 19, 20]. In addition, high lymphocyte-to-monocyte ratio [21], PLR [22], and CRP level [23] have been shown to be associated with poor prognosis in patients with advanced HCC. In our study, increasing NLR was also a poor prognostic factor in patients with advanced HCC (Table 3).…”

Section: Discussion/conclusionmentioning

confidence: 99%

Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study

et al. 2022

View full text Add to dashboard Cite

Introduction: Although many treatment options are available for patients with advanced hepatocellular carcinoma and Child–Pugh class A, those for patients with Child–Pugh class B remain limited. We aimed to assess the safety and efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma and Child–Pugh class B. Methods: Sixty patients who received hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin at Kurume Chuo Hospital between April 2012 and March 2021 were recruited. Cisplatin (30 mg administered over 2 hours) and 5-fluorouracil (1,250 mg, 72-hour constant infusion) were administered to the tumor-feeding artery every 2 weeks. The primary endpoint was overall survival, while the secondary endpoints were progression-free survival and adverse effects. Results: Among the 60 patients, Child–Pugh class A and class B were noted in 30 patients each. Overall survival did not significantly differ between the two classes. After 4 weeks of hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin, 12 patients in the class B group exhibited improved Child–Pugh scores relative to those at the start of treatment. There was a significant difference in overall survival between patients whose Child–Pugh scores had improved and those whose scores remained unchanged or had worsened. Conclusions: Hepatic arterial infusion chemotherapy using 5-fluorouracil and cisplatin is effective and safe for patients with Child–Pugh class B, and improvements in Child–Pugh scores after 4 weeks of this therapy may represent a predictive marker of treatment efficacy regardless of pretreatment Child–Pugh score in Child–Pugh B patients.

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%

Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Inflammation is a well-known hallmark of cancer and is substantially attributed to the development and progression of malignancies ( 16 ). In solid tumors, local immune response and systemic inflammation were correlated with disease progression and patient survival ( 11 , 17 , 18 ). ICIs are now known as an efficient therapy for patients with advanced HCC.…”

Section: Discussionmentioning

confidence: 99%

Predictive role of the monocyte-to-lymphocyte ratio in advanced hepatocellular carcinoma patients receiving anti-PD-1 therapy

Zhu¹,

Zhuang²,

Zhang³

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: The immune checkpoint inhibitor (ICIs) therapy has been proven effective in a range of solid tumors including hepatocellular carcinoma (HCC), non-small cell lung carcinoma and metastatic melanoma.However, only a subset of approximately 20% of patients shows an objective response to anti-PD-1 therapy in HCC. Furthermore, the response to anti-PD-1 therapy is not correlated with programmed cell death 1 ligand expression in tumor tissue. Therefore, it is urgent to identify a biomarker to predict the response of anti-PD-1 therapy.

show abstract

“…In contrast, the lymphocytes play an important role in suppressing cancer cell proliferation and migration: tumor-infiltrating lymphocytes (TILs) are associated with tumor control because they are responsible for both cellular and humoral antitumor immune responses [ 24 ]. Likewise, the monocytes associated with malignant tissue, called tumor-associated macrophages (TAM), contribute to angiogenesis and lymphangiogenesis, which lead to increased cancer cell proliferation [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

The Role of Pre-treatment Inflammatory Biomarkers in the Prediction of an Early Response to Panitumumab in Metastatic Colorectal Cancer

Lasagna¹,

Muzzana²,

Klersy³

et al. 2022

Cureus

View full text Add to dashboard Cite

Background Systemic inflammation is a critical component of the development and progression of several types of cancer. Neutrophil-lymphocyte ratio (NLR) and lymphocyte-monocyte ratio (LMR) are simple, inexpensive, and reliable predictors of the systemic inflammatory response to the therapy in different malignant tumors, including colorectal cancer. Methods Metastatic colorectal cancer (mCRC) patients treated with panitumumab plus chemotherapy at first-line at the medical oncology unit of Fondazione Institute for Research, Hospitalization and Health Care (IRCCS) Policlinico San Matteo di Pavia between January 1st 2016 and February 1st 2021 were retrospectively analyzed. NLR and LMR were divided into two groups (high and low) based on the cut-off points, with the estimation of the prognostic accuracy of NLR for the early treatment response as the primary end-point of this study. Results The receiver operating characteristic (ROC) analysis showed a fair prognostic accuracy of NLR for early treatment response (area under the curve (AUC)=0.76, 95% CI: 0.62-0.89). A slightly lower prognostic accuracy was found for LMR (AUC=0.71, 95% CI: 0.57-0.85). In the univariable proportional hazard Cox model, no effect of NLR on PFS was found (NLR High vs. NLR Low HR=1.3; 95% CI: 0.7-2.4, p=0.414). Patients with higher levels of LMR showed a trend towards higher PFS (LMR High vs. LMR Low HR=0.4; 95% CI: 0.2-1.1, p=0.066). No association was found between NLR (or LMR) and skin toxicity. Conclusions NLR and LMR may be used as biomarkers of prognostic accuracy for the early treatment response in mCRC patients treated with panitumumab.

show abstract

Prognostic Impact of Monocyte to Lymphocyte Ratio in Clinical Outcome for Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Cited by 14 publications

References 48 publications

Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study

Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study

Predictive role of the monocyte-to-lymphocyte ratio in advanced hepatocellular carcinoma patients receiving anti-PD-1 therapy

The Role of Pre-treatment Inflammatory Biomarkers in the Prediction of an Early Response to Panitumumab in Metastatic Colorectal Cancer

Contact Info

Product

Resources

About